Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26920893.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0024 and PMC identifier 5061034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Repurposing agents approved for other indications to radiosensitize tumors may be advantageous. The study by Hill and colleagues utilizes nelfinavir, an HIV protease inhibitor (PI), in combination with radiotherapy in rectal cancer in a prospective study. This combination may improve tumor perfusion and regression compared with radiotherapy alone.
Medical subject headings
- Nelfinavir
- Radiation-Sensitizing Agents
- Rectal Neoplasms